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Background. Breast cancer treatments often result in upper extremity functional limitations in
both the short and long term. Current evidence makes comparisons against a baseline or
contralateral limb, but does not consider changes in function associated with aging.
Objective. The objective of this study was to compare upper extremity function between
women treated for breast cancer more than 12 months in the past and women without cancer.
Design. This was an observational cross-sectional study.
Methods. Women who were diagnosed with breast cancer and had a mean post–surgical
treatment time of 51 months (range = 12–336 months) were compared with women who did not
have breast cancer (CTRL group). Self-reported upper extremity function using the Disabilities
of the Arm, Shoulder and Hand (DASH) questionnaire and shoulder range of motion, strength,
and muscular endurance were measured. Participants were divided into 3 groups: breast cancer
involving the nondominant limb (BC-ND), breast cancer involving the dominant limb (BCDOM), and CTRL.
Results. A total of 59 women in the CTRL group, 23 women in the BC-ND group, and 28
women in the BC-DOM group completed measures. Mean DASH scores in women with breast
cancer were higher than those of women in the CTRL group, regardless of the limb on which
cancer occurred (Cohen d = 1.13; CI95 = 2.20 to 16.21). Range of motion for the BC-ND group
was significantly less for flexion (Cohen d =1.19, CI95 = -13.08 to -0.11) and external rotation
(Cohen d =1.11, CI95 = -18.62 to -1.98) compared with the CTRL group. Strength in the BC-ND
group was 23% to 25% lower in the CTRL group for external (Cohen’s d =0.89, CI95 = 0.09 to
0.12) and internal rotation (Cohen d =0.92, CI95 = 0.10 to 0.13). Endurance was not significantly
different in the 3 groups.

Limitations. Some participants had rehabilitation, which may have skewed results. The range
of post–surgical treatment times was broad, making it difficult to determine when function
returned. Muscular endurance measures demonstrated a ceiling effect and large variance,
limiting the ability to distinguish differences among participants. These results may not be
generalizable to the subset of women who were treated with lumpectomy, sentinel node biopsy,
or chest wall radiation alone or who underwent a contralateral prophylactic mastectomy.
Conclusion. In the long term, women with breast cancer have lower self-reported shoulder
function than women without breast cancer. Motion and strength are lower among women who
have experienced cancer on the nondominant limb.

With the 5-year survival rate of breast cancer at nearly 90%, currently over 3 million women are
living after a diagnosis of breast cancer.1 Upper extremity functional deficits following surgical
and radiation treatments persist beyond the first year.2-4 Declines in upper extremity function
compared with a precancer level are self-reported in 21% to 35% of women treated for breast
cancer up to 6 years following diagnosis.5,6 The more involved the treatment, the greater risk of
upper extremity morbidity. In women surgically treated with mastectomy and axillary lymph
node dissection (ALND) and in women who undergo axillary radiation, upper extremity deficits
in function are reported at greater levels than in women with lumpectomy and/or sentinel node
dissection surgeries.7 The extent of these reported deficits and whether they can be attributed to
breast cancer surgery and treatment or to normal aging have not been examined adequately.
Functional performance of the upper extremity includes adequate levels of arm motion,
strength, and muscular endurance. Declines in motion are reported among women treated for

breast cancer in the long term, with one study reporting >10% decline in flexion more than 5
years following treatment for breast cancer,8 and another study identifying that losses of
≥20degrees of motion were present 7 years after surgical treatment.9 Upper extremity strength
declines of 10% to 15% are reported 1 to 5 years after treatment for breast cancer.10 Muscular
endurance, the ability to sustain an activity over time, has been minimally examined among
women with breast cancer but conflicting results from no deficits11 to a 20% deficit in muscular
endurance are reported.12,13 To date, studies on upper extremity functional performance in
women with breast cancer have primarily used self-reported measures or measured changes
relative to the contralateral limb, assuming this limb is without deficit and functions similarly.
Direct comparisons to a group of women with similar ages without breast cancer have not been
reported for women who have been diagnosed with breast cancer long term. Furthermore, range
of motion (ROM) and strength among women who are healthy is dependent on limb
dominance14,15; therefore, involved limb dominance should be considered when making
comparisons between these groups.
Deficits in self-reported and objective measures of upper extremity function among longterm survivors of breast cancer may be in part a result of changes seen with normal aging. Direct
comparisons of upper extremity function measured by self-report, ROM, strength, and muscular
endurance between women with BC and women who are healthy are important to determine
whether existing deficits are due to treatment or normal aging. The purpose of this study was to
compare upper extremity function of long-term survivors of breast cancer to a population of
women without breast cancer.
[H1] Methods
[H2] Participants

A convenience sample of 59 women who were healthy (CTRL group), 25 women with breast
cancer on the nondominant limb (BC-ND group), and 29 women with breast cancer on the
dominant limb (BC-DOM group) recruited via word-of-mouth, flyers, and email agreed to
participate. All participants were between 40 and 69 years. The CTRL group had no history of
breast cancer, while the BC groups underwent at least 1 of the following treatments a minimum
of 12 months prior to participation: mastectomy, ALND, axillary radiation. Participants were
excluded if they had any history of shoulder, cervical, or thoracic spine pathology diagnosed by a
physician within the previous 6 months or any history of shoulder, cervical, or thoracic surgery
so as to not confound findings. Women with prophylactic contralateral mastectomies were also
excluded to be able to clearly measure involved versus uninvolved sides. One participant with
breast cancer was excluded after screening revealed she had undergone rotator cuff surgery on
her involved side prior to the cancer diagnosis. Two other participants with breast cancer were
excluded after clarification that the radiation received was local to the tumor site and not the
axilla. The final analyses included 23 women in the BC-ND group and 28 women in the BCDOM group.
Sample size was based a priori on a study examining self-reported function between
women with and without breast cancer. Using the mean Disabilities of the Arm, Shoulder, and
Hand (DASH) scores and flexion ROM measures between women with breast cancer 6 months
after treatment and healthy controls,16 the power calculation resulted in an estimated 14 to 16
participants per group required to meet a power of 90%. The study procedures were explained to
all participants, and, after questions were answered, each completed consent prior to data
collection. This study was approved by the Institutional Review Boards of the University of

Kentucky, Lexington, Kentucky, the University of Dayton and Miami Valley Hospital, Dayton,
Ohio.

Procedures
On a single visit, each participant’s objective upper extremity function was measured by a
battery of tests--bilateral shoulder ROM and strength in 3 planes, and muscular endurance using
the Functional Impairment Test–Hand and Neck, Shoulder, Arm (FIT-HaNSA)--by 1 of 3 trained
investigators.17 Participants completed a demographic questionnaire, the International Physical
Activity Questionnaire (IPAQ), and the DASH prior to completing other components of testing.
Demographic variables of age and arm dominance were recorded, and height and weight were
measured to determine body mass index.

[H2] Participant-Reported Measures
Activity level was measured by the 7-item IPAQ, which has good test-retest reliability
(Spearman r = 0.70–0.90).18 Self-reported upper extremity function was measured by the
DASH, a 30-item disability scale scored 0 to 100; lower scores denote less disability. Construct
and convergent validity have been established with other shoulder functional scales, and the testretest reliability within the breast cancer population is excellent (ICC = 0.97).19-22

[H2] Objective Clinical Measures
Range of motion. Bilateral active ROM of shoulder flexion, external rotation (ER), and hand
behind back (HBB) were measured by taking photographs of the participant completing each
motion. The HBB motion was chosen as a representation of a functional measure of internal

rotation, often utilized clinically. Degrees of motion were calculated using ImageJ (National
Institutes of Health, Washington, DC, USA) by the primary investigator. The ICC for intrarater
reliability of digital measurement of ROM was consistently >0.95, with a standard error of
measurement <2 degrees.
Shoulder flexion and ER measurements were taken by placing markers along the axes of
motion as described by Norkin and White23; the marker for the HBB measure was placed at the
level of the C7 spinous process.24,25 Shoulder flexion measurements were taken in standing; ER
was taken with the participant’s upper arm supported on 2 towels while the participant was lying
supine with the arm at 90 degrees of abduction and 90 degrees of elbow flexion. Participants
were instructed to complete the motion as far as possible, and a photograph was taken at this end
range. This procedure was repeated twice bilaterally with the mean of the 2 measurements used
for analysis.23 The shoulder flexion angle was the intersection of 2 lines, one representing the
shoulder and the other the thorax (Fig. 1a). The shoulder ER angle was formed by a line drawn
through the shaft of the ulna and a line perpendicular to the plinth (Fig. 1b). To measure the HBB
distance, a 10-cm reference was placed in the same plane as the participant to provide a spatial
scale of the image for accurate measurement.26 The distance in centimeters from the C7 spinous
process to the spinous process in line with the tip of the thumb was recorded (Fig. 1c).24 A lower
value indicates greater motion. Interrater reliability of the ROM procedures was established in
pilot testing of 8 female adults who were healthy prior to data collection (ICCs = 0.90-0.99).
[H2] Strength. The strength of the shoulder flexors, internal rotators, and external rotators was
measured by handheld dynamometry (Lafayette Manual Muscle Test System, Lafayette
Instruments, Lafayette, IN, USA) using standard testing positions.27 An inelastic nylon strap (~5
cm [2 in] wide) was placed around the participant’s limb and the tester’s body for each motion to

provide a consistent, immovable resistance for the handheld dynamometer (Fig. 2).28-30 Each
participant was instructed to generate force to a maximal level over 5 seconds in each direction
of testing.31,32 Two submaximal practice trials were completed prior to testing, followed by 3
trials with 10 seconds rest in between. The average strength in kilograms (kg) of the 3 trials was
used for statistical analysis.33 Strength was normalized to body weight and is presented as a
percentage of body weight (kilograms of force/body weight in kilograms). Shoulder flexion was
measured with the participant seated, arm elevated to 90 degrees (Fig. 2a).27 To measure IR and
ER, the upper arm was supported on 2 towels while the participant was lying supine with the arm
at 90 degrees of abduction and 90 degrees of elbow flexion (Fig. 2b, 2c).27 In pilot testing with 8
participants, the ICCs for interrater reliability for strength measures ranged from 0.78 to 0.80,
and the standard error of measurement was consistently below 1.2% of body weight.

[H2] Muscular endurance. Upper extremity muscular endurance was measured by the FITHaNSA subtests 2 and 3 following a previously established protocol for performance and
termination of testing.17 The FIT-HaNSA challenges muscular endurance through the completion
of a series of repetitive tasks involving lifting 1 kg from eye level down 25 cm, and a sustained
manipulation task with nuts and bolts above the head (Fig. 3a, 3b). The FIT-HaNSA
demonstrates good-excellent test-retest reliability (ICC = 0.79–0.97), and moderate concurrent
validity (r = 0.71–0.76) with self-reported upper extremity functional scales (Fig. 3 and 4).17,27
[H2] Data Analysis
Participants with breast cancer were divided into groups based on which side the cancer
occurred: dominant (BC-DOM group) or nondominant (BC-ND group). For comparison
analyses, the same limb was used for both the CTRL and BC groups: BC-DOM was compared to

the dominant limb of the CTRL group, whereas BC-ND was compared to the nondominant limb
of the CTRL group For analyses that did not depend on laterality, the full BC group (ie, both the
BC-DOM group and the BC-ND group) was compared to the CTRL group.
Descriptive statistics were calculated for all variables. Data were examined for
assumptions of normality using Kolmogorov-Smirnov test. All data were normally distributed (p
<.05) except for the DASH and FIT-HaNSA scores. Because the sample size is robust and the
variance small, the DASH and FIT-HaNSA were evaluated with parametric tests, consistent with
other literature in this area.5,17 Participant demographics of age, body mass index, activity level,
and DASH scores were compared using a 1-way analysis of variance (ANOVA). Separate
multivariate analyses of variance (MANOVA) were used to analyze all ROM, strength, and
muscular endurance measures. For each MANOVA, Box Tests of Equality of Covariance
Matrices were used to test assumptions of homogeneity. When significance was found on the
ANOVA and MANOVA, Games-Howell post hoc testing determined the direction of
significance based on unequal group sizes with unequal variances.34 Cohen d was used to
calculate effect sizes. Significance was established a priori at P ≤ 05. All data were analyzed
using IBM SPSS Statistics 23 (Chicago, IL, USA).
[H1] Results
The ANOVA revealed no significant differences in potential confounders of age (P =
.23), body mass index (P =.59), and activity levels (P =.78) among the 3 groups. Among
participants with breast cancer, the median duration since surgical treatment was 51 months
(range = 12–336); 34 (66.7%) underwent a mastectomy, 17 (33.3%) underwent ALND, and 12
(23.5%) had axillary radiation. Of these, 23 (45.1%) underwent a mastectomy alone, 5 (9.8%)
had both a mastectomy and ALND, 6 (11.8%) underwent an ALND and axillary radiation, and 6

(11.8%) underwent all 3 procedures. Of the 34 women who underwent a mastectomy, data on
reconstruction status were available from 26 (76.5%), with 11 (42.3%) women not having
reconstructive surgery, 12 (46.2%) having implant reconstruction, 2 (7.7%) having transverse
rectus abdominis myocutaneous (TRAM) flap reconstruction, and 1 (3.8%) %) having latissimus
reconstruction. More than half of the participants (60%) who answered the question about prior
rehabilitation intervention for their shoulder did not have previous treatment. Of those who
received rehabilitation, the majority received lymphedema treatment and education, with a small
portion receiving exercise to improve motion. Enrolled participants came from a broad
geographic area including 5 counties encompassing urban, suburban, and rural locales.
Participant demographics are detailed in Table 1.
The ANOVA for the DASH resulted in statistically significant differences between both
BC groups and controls. Tukey post hoc testing revealed significant differences among the BCDOM and CTRL groups (P ≤ .001) and the BC-ND and CTRL groups (P =.008) (Tab. 2). The
Box Test of Equality of Covariance Matrices was not significant (P >.01) for ROM, strength, or
muscular endurance, indicating that the covariance matrices of the dependent variables were
equal across groups. The MANOVA for ROM measures revealed statistically significant
differences between the BC-ND and CTRL groups (P ≤.001). Games-Howell post hoc testing
indicated that the BC-ND group had statistically significantly less flexion (P =.006) and ER (P
=.009) motion than the CTRL group (Tab. 2). Strength was significantly less in the BC-ND
group for shoulder internal (P ≤.001) and external rotation (P =.003) than for the CTRL group
(Tab. 2). FIT-HaNSA testing resulted in no statistically significant differences between groups
(P >.05).

[H1] Discussion
This unique study directly compared DASH scores and shoulder ROM, strength, and
muscular endurance between women with BC and healthy controls, while considering involved
limb dominance. To our knowledge ,these comparisons have not been investigated among longterm survivors of breast cancer. The results suggest that persistent deficits may be a result of
breast cancer treatment and are not due to aging. Women treated for breast cancer report higher
DASH scores (disability) regardless of which limb is involved. Those with cancer affecting their
nondominant limb demonstrate less upper extremity ROM and strength than a control sample of
women without breast cancer. Based on these findings, clinical interventions may need to be
different based on the side affected by breast cancer.
DASH scores were statistically significantly higher among women with breast cancer
compared with levels reported by the healthy sample, implying lower levels of overall upper
extremity function. Caution should be exercised, however, as this level of perceived function
may not be clinically relevant when compared to DASH values in a larger population. The mean
DASH score of a general population sample of 1706 adults was 10.1 (SD = 14.7),35 and among
327 women aged 18 to 65 years, the mean DASH score was 14.3 (SD = 14.9).36 That the control
population in this study reported DASH scores much lower than the general population is likely
due to study criteria for participation that included no current shoulder dysfunction. In a
comparison of our results (mean score = 12.0–12.3) to a general population, our sample of
women with breast cancer who were on average 4 years posttreatment reported similar levels of
function. These findings indicate that women with breast cancer can expect recovery of function
similar to the population as a whole with adequate time. Yet months to years after treatment,
over 20% of women treated for breast cancer score ˃20 on the DASH.5 Given the large effect

sizes of the results, the findings in our study may suggest that the diagnosis of cancer can overlay
the reality of recovery and that women treated for breast cancer continue to perceive that
recovery is incomplete. The self-reported function of the BC groups remains lower than that of
our control population without shoulder impairment.
Nearly all ROM measures in participants with breast cancer were impaired by 4% to 12%
compared with a healthy sample even 4 years after treatment. Only the HBB measure was not
significantly diminished, yet in terms of raw numbers, the BC-DOM group demonstrated 3.5%
less motion than the control group, whereas those with cancer on the nondominant side
demonstrated 23% less motion. This greater loss on the nondominant side suggests greater
impact of the cancer experience on this side. The mean shoulder flexion motion among
participants with breast cancer in this study is 12 to 17 degrees less than that reported among
women with breast cancer within the first 6 months after treatment,16 suggesting that shoulder
flexion ROM loss may continue past 1 year. Although none of the averages of motion are below
what is generally accepted as a clinically significant level, a minimum range of 148 degrees of
shoulder flexion is documented as necessary for reaching a high shelf.37 A secondary analysis of
participants with breast cancer with motion <148 degrees revealed that 30 of 51 (59%) of these
participants did not have this level of motion available on the involved limb. The ER motion,
although statistically significantly less in the BC-ND group, is not considered to be clinically
deficient at 83 degrees, as most functional tasks can be completed with this available range.
Although women with breast cancer 4 years following treatment generally demonstrate ROM at
an adequate level to complete most daily activities, these women may have difficulty completing
tasks requiring what is generally accepted as full ROM, such as reaching to higher heights or
participating in overhead activities. Furthermore, the effect sizes of these results (>1) suggest

that the differences seen are greater than 1 standard deviation from the mean. It is important to
understand that even 4 years after treatment, these women demonstrate motion at levels less than
their peers without breast cancer.
Strength differences compared to the CTRL group were found to affect primarily
participants who had cancer on their nondominant side. This group demonstrated strength
impairments in both IR and ER that show a 26% to 28% deficit compared with a population of
women without a history of breast cancer. Additionally, the strength values of participants with
breast cancer in this study are more than 30% less than published reference values for a healthy
population of similarly aged women.14,31 Although methodologies for measurement differed
slightly (flexion resistance at the epicondyle instead of distally at the ulnar styloid process14 and
rotation positioning at 45 degrees14,31 instead of 90 degrees of abduction used in this study), the
deficits appear greater than can be explained by differing methodologies. It is possible that
recovery of strength does not occur spontaneously but with use of the upper extremity, and the
lack of apparent recovery seen in participants with breast cancer whose involved limb is
nondominant may be due to lower levels of nondominant limb use in daily activities. In studies
of arm activity using accelerometry individuals who are healthy, the nondominant limb typically
has less activity than the dominant limb.38 This loss of strength occurring in the involved
nondominant limb was interesting because the strength deficits were not observed in the
dominant limb, suggesting that women with breast cancer involving the nondominant limb may
need to to have their rehabilitation for breast cancer managed differently than women with breast
cancer in their dominant limb.
Research on muscular endurance among women with breast cancer is limited. Two
published studies that have examined muscular endurance have used the Upper Body Strength

and Endurance Test, for which psychometric data are unavailable.39,40 Results from these studies
show less endurance in the involved limb compared with the noninvolved limb. The current
study is the first study to examine the use of the FIT-HaNSA in a population of women with
breast cancer. Findings in this study indicate that upper extremity endurance is not impaired
compared with a similar healthy population. The lack of differences found between groups may
be due to the level of variance between the 2 groups. A large ceiling effect was observed in
performing the FIT-HaNSA; 66% to 81% of the CTRL group completed the full test duration of
300 seconds, and 53% to 76% of participants with breast cancer completed the full test.
Examining muscular endurance with a more responsive test without a ceiling effect might
provide a clearer picture of the level of muscular endurance among women with breast cancer.
When examining the statistically significant deficits in light of clinical relevance in
DASH scores, ROM, and involved nondominant limb strength, we determined that most daily
activities can be completed at reported levels, but it is higher level functional activities that may
be compromised among this group of women with breast cancer. The DASH outcome measure
was designed to evaluate an overall level of disability, and questions are answered based on an
individual’s ability to perform a task regardless of limb used.41 This may explain why scores
among participants with breast cancer are similar to those in a healthy population, as not all tasks
would be performed with the involved limb. Additionally, this outcome measure asks only 1 out
of 30 questions related to reaching overhead and therefore may not be capturing disabilities
related to reaching overhead to higher levels. The limitation to higher ROM seen in nearly 60%
of participants suggests that although most daily tasks can be completed, tasks that require
greater motion, such as reaching high shelves or participating in overhead activities, may be
difficult to perform. Certainly, clear deficits in strength are noted among women who

experienced breast cancer on their nondominant side, and this strength deficit can affect the
ability to complete more demanding functional tasks that require higher levels of strength.

Several limitations in this study may have impacted the results. As the sample was
limited to women with more involved cancer treatments, these results may not be generalizable
to the subset of women who were treated with lumpectomy, sentinel node biopsy, or chest wall
radiation alone or who underwent a contralateral prophylactic mastectomy. Incomplete data
regarding rehabilitation intervention after surgical treatment for cancer and before data collection
makes analysis of the impact of intervention difficult. It is possible that those who had
interventions directed toward upper extremity functional return may have skewed the results.
Incomplete data about how many women underwent reconstructive surgery is also a limitation;
the impact of reconstructive surgery on arm function cannot fully be assessed. However, with
two-thirds of those who had a mastectomy reporting on reconstruction status, it appears that
about half of the sample who had mastectomies underwent reconstruction. In addition, the range
of time after breast cancer treatment was long (12–336 months) and therefore may have allowed
normal tissue healing to occur, thus mitigating long-term functional deficits. A longitudinal study
would help differentiate at what point in time following treatment breast cancer symptoms
improve, giving insight into the probable time line for return of function. The variance associated
with the FIT-HaNSA was large (>60 seconds), suggesting that the measure was not sensitive
enough to identify those individuals with decreased endurance. Furthermore, the significant
ceiling effect does not allow for discrimination between groups.

[H1] Conclusion
Although long-term survivors of breast cancer often report upper extremity functional
limitations, the results of this study indicate that, at an average of 4 years posttreatment, most
women recover ROM and strength to levels comparable to women of similar ages without breast
cancer. The important new finding focuses on which limb was involved with cancer treatment.
Those women whose cancer impacted the nondominant limb appear to demonstrate long-term
deficits that their counterparts with dominant involved limb do not. Although the clinical
relevance of these statistically significant lower ROM and strength values in women with
nondominant involvement may not seem important, these women continue to report functional
deficits higher than their counterparts without shoulder dysfunction. The fact that most daily
tasks could be completed with the available ROM and strength measured showed some recovery
of function. These findings--a loss of shoulder flexion motion that can impact certain activities
requiring a higher reach and the unexpected finding that strength deficits affect only those who
have experienced cancer in the nondominant limb--have not been previously reported. As such,
the findings in this study present a novel and important consideration in the treatment of women
with breast cancer on the nondominant side. These findings were the most meaningful
differences that require further investigation.
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Figure Legend:
Fig 1a Flexion ROM
Arc of motion generated for illustrative purposes only by Kinovea.org
Fig 1b External Rotation ROM
Arc of motion generated for illustrative purposes only by Kinovea.org
Fig 1c Hand Behind Back Motion
Fig 2a Flexion Strength
Fig 2b Internal Rotation Strength
Fig 2c External Rotation Strength
Fig 3a FIT-HaNSA sub-test 2
Fig 3b FIT-HaNSA sub-test 3

Tables:

Table 1. Participant Demographics, Mean (SD)
BCS Non-dominant
(n=23)

BCS Dominant
(n=28)

Control
(n=59)

Age, years (range)

57 (41-67)

56 (41-69)

54 (40-68)

BMI

28.3 (6.4)

27.3 (5.9)

26.8 (5.4)

2580 (2441)

3071 (4567)

3190 (2926)

IPAQ, mets
Time since surgery, months
(range)

51 (12-336)

Surgery
Mastectomy alone

8

15

Mastectomy + ALND

3

2

Mastectomy + ALND +
Axillary Radiation

3

3

ALND + Axillary
Radiation

4

2

5

11

Previous Rehabilitation
(n=35)

BCS = Survivor of breast cancer; BMI = Body Mass Index; IPAQ = International Physical Activity Questionnaire;
ALND = Axillary Lymph Node Dissection
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Table 2. Outcome Measures, Mean (SD)

DASH

BCS Nondominant
(n=23)

Control Nondominant
(n=59)

p
value

CI

Cohen’s
d

BCS Dominant
(n=28)

Control
Dominant
(n=59)

p
value

CI

Cohen’s
d

12.3 (13.1)

3.3 (4.6)

0.008*

2.20, 16.21

1.13

12.0 (11.6)

3.3 (4.6)

≤0.001*

3.33, 14.36

1.13

Range of Motion (in degrees except as noted)
Flexion

140 (17)

154 (9.0)

0.006*

-13.08, -0.11

1.19

146 (14)

152 (9.0)

0.07

-13.57, .46

0.55

External
Rotation

83 (15)

94 (7.0)

0.009*

-18.62, -1.98

1.11

90 (12)

95 (9.0)

0.15

-11.02, 1.17

0.50

HBB (cm)

16.6 (6.3)

13.5 (4.1)

0.092

-1.09, 4.13

0.64

17.6 (5.4)

17.0 (4.5)

0.83

-2.16, 3.50

0.12

Strength (% of body weight)
Flexion
External
Rotation
Internal
Rotation

7.3 (3.1)

8.7 (3.1)

0.24

-0.03, 0.01

0.45

8.5 (3.0)

9.2 (3.0)

0.06

.73, .97

0.23

10.3 (4.7)*

14.3 (4.4)

0.003*

0.09, 0.12

0.89

14.3 (5.4)

14.3 (4.2)

0.27

0.12, 0.16

0.0

10.5 (3.5)*

14.2 (4.2)

0.001*

0.10, 0.13

0.92

12.7 (4.2)

14.3 (4.5)

0.99

0.11, 0.14

0.36

Muscular Endurance (in seconds)

FIT-HaNSA
2

237.1 (86.7)

262.7 (67.7)

0.42

-63.74, 19.93

0.35

246.0 (77.8)

269.7 (56.8)

0.35

-64.04, 17.33

0.37

FIT-HaNSA
3

257.7 (69.4)

281.1 (45.1)

0.31

-61.90, 15.19

0.44

269.9 (67.2)

281.1 (45.1)

0.71

-45.89, 23.49

0.21

2
3
4

*Significant at alpha ≤0.05
BCS = Survivor of breast cancer; CI = confidence interval; DASH = Disabilities of the Arm, Shoulder, Hand; FIT-HaNSA = Functional Impairment Test-Hand
and Neck, Shoulder, Arm; HBB = hand behind back
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Figure 2a
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